NeuBase Therapeutics, Inc. announced earnings results for the third quarter ended June 30, 2021. For the third quarter, the company announced operating loss was USD 8.839 million compared to USD 3.824 million a year ago. Net loss was USD 8.662 million compared to USD 3.799 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.18 a year ago. For the nine months, operating loss was USD 19.396 million compared to USD 11.961 million a year ago. Net loss was USD 18.250 million compared to USD 12.683 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 0.69 a year ago.